Trial Profile

A Phase 1 First-in-human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-787 in Adult Subjects With Acute Myeloid Leukemia (AML)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV-787 (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man
Sponsors AbbVie

Most Recent Events

06 Mar 2025 Status changed from recruiting to discontinued as per strategic considerations
29 Mar 2024 Planned End Date changed from 12 Dec 2029 to 20 Oct 2029.
29 Mar 2024 Planned primary completion date changed from 12 Dec 2029 to 20 Oct 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com